World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
32090
World Ranking
13048
National Ranking
387

Tomohide Tamura publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Tomohide Tamura sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 624 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Tomohide Tamura D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Tomohide Tamura sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Tomohide Tamura is affiliated with St. Luke's International Hospital in Japan and has made contributions primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research encompasses several subfields, including Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Surgery, and Cancer Research.

The scientist's work centers on topics such as Lung Cancer Treatments and Mutations, Pancreatic and Hepatic Oncology Research, Gallbladder and Bile Duct Disorders, Extracellular vesicles in disease, Lung Cancer Research Studies, Pediatric Hepatobiliary Diseases and Treatments, and Cancer Immunotherapy and Biomarkers.

Among the recent notable publications by Tomohide Tamura are:

  • Extracellular vesicles as a promising biomarker resource in liquid biopsy for cancer (2021) in Extracellular Vesicles and Circulating Nucleic Acids
  • Extracellular Vesicles in Bone Metastasis: Key Players in the Tumor Microenvironment and Promising Therapeutic Targets (2020) in International Journal of Molecular Sciences

These publications illustrate a focus on extracellular vesicles and their implications in cancer diagnosis and treatment. The scientist has extensive collaboration with peers, frequently co-authoring with:

  • Shinichi Sakamoto
  • Tomohiko Ichikawa
  • Nobuyuki Hizawa
  • Masayuki Kitano
  • Toshihiro Shiozawa

Tomohide Tamura has contributed to multiple articles published in journals such as Anticancer Research, In Vivo, Gastrointestinal Endoscopy, Extracellular Vesicles and Circulating Nucleic Acids, and International Journal of Molecular Sciences. The frequency of publications highlights ongoing research in oncology and molecular biology-related topics within these specialized venues.

Their work in pulmonary and respiratory medicine aligns with key research themes such as lung cancer treatments and immunotherapy, showing an interdisciplinary approach bridging molecular insights with clinical applications. The focus on extracellular vesicles underscores the growing interest in cell-derived components as biomarkers and therapeutic targets within cancer research.

Overall, the scientific profile of Tomohide Tamura reflects a research trajectory deeply connected with cancer biology, clinical oncology, and molecular diagnostics, supported by a network of frequent collaborators and contributions to respected scientific journals.

Best Publications

  • Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

    Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura

  • Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

    Kazumasa Noda;Yutaka Nishiwaki;Masaaki Kawahara;Shunichi Negoro

  • Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

    Toshimi Takano;Yuichiro Ohe;Hiromi Sakamoto;Koji Tsuta

  • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

    Y Ohe;Y Ohashi;K Kubota;T Tamura

  • Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

    Toyoaki Hida;Hiroshi Nokihara;Masashi Kondo;Young Hak Kim

  • Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104

    Minoru Takada;Masahiro Fukuoka;Masaaki Kawahara;Takahiko Sugiura

  • CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

    Takashi Seto;Katsuyuki Kiura;Makoto Nishio;Kazuhiko Nakagawa

  • Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

    Masahiro Fukuoka;Kiyoyuki Furuse;Nagahiro Saijo;Yutaka Nishiwaki

  • Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

    Antonio Rossi;Massimo Di Maio;Paolo Chiodini;Robin Michael Rudd

  • Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

    Riichiroh Maruyama;Yutaka Nishiwaki;Tomohide Tamura;Nobuyuki Yamamoto

  • Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer

    Hideharu Kimura;Kazuo Kasahara;Makoto Kawaishi;Hideo Kunitoh

  • Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer

    Ramaswamy Govindan;Aleksandra Szczesna;Myung Ju Ahn;Claus Peter Schneider

  • Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

    K. Nakagawa;T. Tamura;S. Negoro;S. Kudoh

  • Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.

    Hideharu Kimura;Kazuko Sakai;Tokuzo Arao;Tatsu Shimoyama

  • Unpredicted Clinical Pharmacology of UCN-01 Caused by Specific Binding to Human α1-Acid Glycoprotein

    Eiichi Fuse;Hiromi Tanii;Noriaki Kurata;Hiroyuki Kobayashi

  • EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

    Toshimi Takano;Tomoya Fukui;Yuichiro Ohe;Koji Tsuta

  • Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)

    Shinji Atagi;Masaaki Kawahara;Akira Yokoyama;Hiroaki Okamoto

  • Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

    Toshimi Takano;Yuichiro Ohe;Masahiko Kusumoto;Ukihide Tateishi

  • Toxicity grading criteria of the japan clinical oncology group

    Kensei Tobinai;Akio Kohno;Yasuhiro Shimada;Toru Watanabe

  • Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.

    Hiromi Fukushima-Uesaka;Yoshiro Saito;Hidemi Watanabe;Kisho Shiseki

Frequent Co-Authors

Yuichiro Ohe
Yuichiro Ohe National Cancer Centre
Nagahiro Saijo
Nagahiro Saijo AstraZeneca (United Kingdom)
Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Kazuto Nishio
Kazuto Nishio Kindai University
Yutaka Nishiwaki
Yutaka Nishiwaki Tokyo Medical University
Hiroaki Okamoto
Hiroaki Okamoto Jichi Medical University
Teruhiko Yoshida
Teruhiko Yoshida National Cancer Research Institute, UK
Masahiro Fukuoka
Masahiro Fukuoka Kindai University
Yoshiro Saito
Yoshiro Saito Tohoku University
Koji Tsuta
Koji Tsuta Kansai Medical University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medical careers, there are flexible online education options that can jumpstart or advance their journey. Many aspiring healthcare professionals begin as registered nurses and later pursue further qualifications. Earning a bachelor’s degree is a common step, and those seeking budget-friendly options can explore the cheapest rn to bsn program choices available online.

For nurses aiming to take on leadership or specialized clinical roles, accredited master’s degrees matter. Affordable opportunities exist for higher education through the affordable np programs and the cheapest online msn programs, both offering convenient online formats.

For advanced positions in research, academia, or clinical leadership, earning a doctorate can be a rewarding path. There are fully online options for those interested in pursuing an online phd nursing degree, allowing greater flexibility for working professionals.

Each of these online pathways caters to different career stages and interests, providing affordable and accessible routes to in-demand roles within the U.S. healthcare system.

Best Scientists Citing Tomohide Tamura

Trending Scientists

Recently Published Articles